THE FIGHT AGAINST MALARIA

摘要

As the director of global access and marketing for the Novartis Malaria Initiative, Hans Rietveld often visits Zambia, one of the African countries that benefits from the initiative through the not-for-profit supply of Novartis' antimalarial. He is touched by the stories he hears from patients about the positive impact this treatment has on their communities. As the first fixed-dose ACT (artemisinin-based combination therapy), it changed the face of malaria treatment globally after the company introduced it in 1999.